These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 32274540

  • 21. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 22. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW.
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [Abstract] [Full Text] [Related]

  • 23. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.
    Kuppen MCP, Westgeest HM, van den Eertwegh AJM, van Moorselaar RJA, van Oort IM, Coenen JLLM, van den Bergh ACMF, Mehra N, Somford DM, Bergman AM, Ten Bokkel Huinink D, Fossion L, Geenen MM, Hendriks MP, van de Luijtgaarden ACM, Polee MB, Weijl NI, van de Wouw AJ, de Wit R, Uyl-de Groot CA, Gerritsen WR.
    Eur Urol Oncol; 2021 Aug; 4(4):618-627. PubMed ID: 31601523
    [Abstract] [Full Text] [Related]

  • 24. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
    González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA.
    Clin Transl Oncol; 2021 May; 23(5):969-979. PubMed ID: 33625671
    [Abstract] [Full Text] [Related]

  • 25. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
    Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, Bompas E, Joly F, Greilsamer C, Hon TNT, Barthelemy P, Culine S, Berdah JF, Deblock M, Ratta R, Flechon A, Cheneau C, Maillard A, Martineau G, Borget I, Fizazi K, Groupe d’Etude des Tumeurs Uro-Genitales (GETUG)..
    Eur Urol; 2022 Mar; 81(3):234-240. PubMed ID: 34789394
    [Abstract] [Full Text] [Related]

  • 26. AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC.
    Erb HHH, Sparwasser P, Diehl T, Hemmerlein-Thomas M, Tsaur I, Jüngel E, Sommer U, Baretton GB, Haferkamp A, Neisius A, Thomas C.
    Urol Int; 2020 Mar; 104(3-4):253-262. PubMed ID: 31955172
    [Abstract] [Full Text] [Related]

  • 27. An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective.
    Morgans AK, Hutson T, Guan AKD, Garcia D, Zhou A, Drea E, Vogelzang NJ.
    BMC Health Serv Res; 2022 Jul 14; 22(1):916. PubMed ID: 35836170
    [Abstract] [Full Text] [Related]

  • 28. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
    O'Sullivan JM, Abramowitz E, Sierra-Scacalossi L.
    Future Oncol; 2023 May 14; 19(15):1021-1028. PubMed ID: 36942803
    [Abstract] [Full Text] [Related]

  • 29. Sequencing Treatment for Castration-Resistant Prostate Cancer.
    Handy CE, Antonarakis ES.
    Curr Treat Options Oncol; 2016 Dec 14; 17(12):64. PubMed ID: 27822685
    [Abstract] [Full Text] [Related]

  • 30. Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
    Arslan C.
    World J Urol; 2017 Mar 14; 35(3):479-480. PubMed ID: 27417948
    [No Abstract] [Full Text] [Related]

  • 31. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.
    Jpn J Clin Oncol; 2015 Aug 14; 45(8):774-9. PubMed ID: 25981621
    [Abstract] [Full Text] [Related]

  • 32. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
    Recine F, Ceresoli GL, Baciarello G, Cerbone L, Calabrò F.
    Q J Nucl Med Mol Imaging; 2015 Dec 14; 59(4):400-10. PubMed ID: 26337241
    [Abstract] [Full Text] [Related]

  • 33. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
    Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J.
    Cancer Treat Rev; 2014 Feb 14; 40(1):170-7. PubMed ID: 23958310
    [Abstract] [Full Text] [Related]

  • 34. Therapy Update for Metastatic Castration-Resistant Prostate Cancer.
    Dinh JA, Baker D, Chahal M.
    Consult Pharm; 2016 Feb 14; 31(10):581-592. PubMed ID: 27725068
    [Abstract] [Full Text] [Related]

  • 35. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
    Bracarda S, Sisani M, Marrocolo F, Hamzaj A, Del Buono S, Altavilla A.
    Expert Rev Anticancer Ther; 2014 Nov 14; 14(11):1283-94. PubMed ID: 25353258
    [Abstract] [Full Text] [Related]

  • 36. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
    Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.
    Urologe A; 2019 Sep 14; 58(9):1066-1072. PubMed ID: 31041460
    [Abstract] [Full Text] [Related]

  • 37. Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.
    Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, Hamberg P, Overkleeft ENM, van der Deure WM, Lolkema MP, de Wit R, Mathijssen RHJ.
    Clin Cancer Res; 2018 Feb 01; 24(3):541-546. PubMed ID: 29150561
    [Abstract] [Full Text] [Related]

  • 38. [Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
    Ohlmann CH, Goebell PJ, Grimm MO, Klier J, König F, Machtens S, Schostak M, Schrader AJ, Albers P.
    Urologe A; 2017 Dec 01; 56(12):1597-1602. PubMed ID: 28695241
    [Abstract] [Full Text] [Related]

  • 39. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM.
    Eur Urol; 2016 Nov 01; 70(5):718-721. PubMed ID: 26852075
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany.
    Wenzel M, Borkowetz A, Lieb V, Hoffmann MA, Borgmann H, Höfner T, Dotzauer R, Neuberger M, Worst TS, von Hardenberg J, Linxweiler J, Klümper N.
    Urol Oncol; 2022 Dec 01; 40(12):538.e7-538.e14. PubMed ID: 36244915
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.